登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，11月27日，Viral epitope profiling of COVID-19 patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-12-22

  • Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
    View ORCID ProfileEllen Shrock1,2,*, View ORCID ProfileEric Fujimura1,2,3,*, View ORCID ProfileTomasz Kula1,2,†, View ORCID ProfileRichard T. Timms1,2,†, View ORCID ProfileI-Hsiu Lee4, View ORCID ProfileYumei Leng1,2,...

    Science  27 Nov 2020:
    Vol. 370, Issue 6520, eabd4250
    DOI: 10.1126/science.abd4250

    Structured Abstract
    INTRODUCTION
    A systematic characterization of the humoral response to severe acute respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed. This analysis is important for understanding the immunogenicity of the viral proteome and the basis for cross-reactivity with the common-cold coronaviruses.

    Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is notable for its variable course, with some individuals remaining asymptomatic whereas others experience fever, respiratory distress, or even death. A comprehensive investigation of the antibody response in individuals with severe versus mild COVID-19—as well as an examination of past viral exposure history—is needed.

    RATIONALE
    An understanding of humoral responses to SARS-CoV-2 is critical for improving diagnostics and vaccines and gaining insight into variable clinical outcomes. To this end, we used VirScan, a high-throughput method to analyze epitopes of antiviral antibodies in human sera. We supplemented the original VirScan library with additional libraries of peptides spanning the proteomes of SARS-CoV-2 and all other human coronaviruses. These libraries enabled us to precisely map epitope locations and investigate cross-reactivity between SARS-CoV-2 and other coronavirus strains. The original VirScan library allowed us to simultaneously investigate antibody responses to prior infections and viral exposure history.

  • 原文来源：https://science.sciencemag.org/content/370/6520/eabd4250
120浏览量
原文链接
相关报告

  • 《Science Advances，2月3日，A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-25
    • A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood Dianna L. Ng1,2,*, View ORCID ProfileAndrea C. Granados2,3,*, Yale A. Santos2,3,*, View ORCID ProfileVenice Servellita2,3,*, View ORCID ProfileGregory M. Goldgof2,... Science Advances  03 Feb 2021: Vol. 7, no. 6, eabe5984 DOI: 10.1126/sciadv.abe5984 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease-19 (COVID-19), has emerged as the cause of a global pandemic. We used RNA sequencing to analyze 286 nasopharyngeal (NP) swab and 53 whole-blood (WB) samples from 333 patients with COVID-19 and controls. Overall, a muted immune response was observed in COVID-19 relative to other infections (influenza, other seasonal coronaviruses, and bacterial sepsis), with paradoxical down-regulation of several key differentially expressed genes. Hospitalized patients and outpatients exhibited up-regulation of interferon-associated pathways, although heightened and more robust inflammatory responses were observed in hospitalized patients with more clinically severe illness. Two-layer machine learning–based host classifiers consisting of complete (>1000 genes), medium (<100), and small (<20) gene biomarker panels identified COVID-19 disease with 85.1–86.5% accuracy when benchmarked using an independent test set. SARS-CoV-2 infection has a distinct biosignature that differs between NP swabs and WB and can be leveraged for COVID-19 diagnosis.  
    91浏览量
    原文链接

  • 《Science，7月15日，Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-07-28
    • Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Divij Mathew1,2,*, Josephine R. Giles1,2,3,*, Amy E. Baxter1,2,*, Derek A. Oldridge1,4,*, Allison R. Greenplate Science 15 Jul 2020: eabc8511 DOI: 10.1126/science.abc8511 Abstract COVID-19 is currently a global pandemic, but human immune responses to the virus remain poorly understood. We analyzed 125 COVID-19 patients, and compared recovered to healthy individuals using high dimensional cytometry. Integrated analysis of ~200 immune and ~50 clinical features revealed activation of T cell and B cell subsets in a proportion of patients. A subgroup of patients had T cell activation characteristic of acute viral infection and plasmablast responses reaching >30% of circulating B cells. However, another subgroup had lymphocyte activation comparable to uninfected subjects. Stable versus dynamic immunological signatures were identified and linked to trajectories of disease severity change. These analyses identified three “immunotypes” associated with poor clinical trajectories versus improving health. These immunotypes may have implications for the design of therapeutics and vaccines for COVID-19.
    28浏览量
    原文链接